High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*Christian J. Wiedermann, Steven M. Opal, Heinz-Otto Keinecke et al.|Critical Care Medicine|2006Cited by 188
Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparinJohannes Hoffmann, Christian J. Wiedermann, Mathias Juers et al.|Thrombosis and Haemostasis|2006Cited by 85
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroupsGuido Bisping, Joachim Kienast|Blood|2005Cited by 36
Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) MyelomaGuido Bisping, Joachim Kienast|Clinical Cancer Research|2009Cited by 32